They Watched Thousands of Families Ask Strangers for Money to Treat Diabetes and Obesity. They Decided to Build Something That Intervenes Earlier.
For 14 years, Ketto has been one of India's most important healthcare infrastructure tools — not because it treats disease, but because it funds treatment when families cannot afford it. Launched in 2012 by Varun Sheth, Zaheer Adenwala, and Kunal Kapoor, the platform has facilitated crowdfunding campaigns for hundreds of thousands of medical cases, connecting people in crisis with donors who could help.
What 14 years of watching those campaigns taught the founders was not primarily about fundraising. It was about disease.
The patterns were impossible to miss. Type 2 diabetes complications requiring surgery. Heart disease in people in their forties. Kidney failure tracing back to years of unmanaged blood sugar. Obesity-related joint disease. Conditions that arrived as acute medical emergencies had, in almost every case, been building slowly and silently for years — in the metabolic health of people who had never been told they were at risk, or who had received a diagnosis but no structured support to manage it.
On July 6, 2026, Kunal Kapoor, Varun Sheth, and Zaheer Adenwala announced the launch of MetaGO — a doctor-led metabolic health platform designed to intervene in those earlier years, before the emergency, before the crowdfunding campaign, before the surgery.
What MetaGO Is — the Platform and the Model
MetaGO is built around a specific and deliberately stated conviction: meaningful metabolic care does not begin and end with a prescription. It begins with a comprehensive understanding of the individual's metabolic profile and continues with the structured, physician-supervised, multi-dimensional support that makes lasting improvement possible.
Every MetaGO member starts with a metabolic assessment covering more than 35 biomarkers — a diagnostic baseline far more comprehensive than a standard GP visit provides — combined with a detailed clinical evaluation. Based on that assessment, a specialist from one of four disciplines — endocrinology, diabetology, cardiology, or internal medicine — develops a personalised treatment plan tailored to the individual's specific metabolic profile and health goals.
GLP-1 therapies — the class of medications including semaglutide and liraglutide that have transformed the treatment options for people living with obesity by producing significant, sustained weight loss when combined with lifestyle changes — are included where clinically appropriate. MetaGO's medical advisory board is explicit about the framing: GLP-1 therapies have genuinely expanded what is possible, but their impact is greatest when combined with proper clinical supervision, metabolic monitoring, and sustained lifestyle support. The medication is one part of the plan, not the plan itself.
Ongoing support — nutrition guidance, fitness coaching, regular clinical reviews, and structured follow-ups — is designed to help members build the habits that sustain improvement over time rather than treating weight management as a short-term intervention.
The entire model is delivered to the member's doorstep. Doctor consultations, diagnostic tests, medication management, and coaching — accessible from home through the platform's digital and in-person service infrastructure.
Kunal Kapoor — Actor, Entrepreneur, and the Person Who Made This Visible
Kunal Kapoor's involvement in MetaGO is not the celebrity endorsement that many health brands use as a launch vehicle. He is a co-founder with 14 years of operational involvement in Ketto before the MetaGO idea was even conceived, and his perspective on why the platform was necessary comes from direct professional experience rather than from brand positioning.
He has been described as one of India's earliest celebrity entrepreneurs — an actor who moved into venture investment and business building before it was the norm, with investments across robotics, AI, biohacking, FMCG, and consumer innovation. He is a Fellow of the Aspen Leadership Programme. His involvement in Ketto, and now MetaGO, reflects a sustained commitment to healthcare access as a professional project rather than a philanthropic gesture.
His statement at the launch is the most precise articulation of what MetaGO was built to address. He is not building a weight-loss company. MetaGO is focused on the years when the right intervention is a doctor's consultation instead of a surgery. GLP-1 therapies have genuinely changed what is possible for many people living with obesity, but medication is only one part of the journey. Lasting outcomes require combining it with medical supervision, nutrition, behaviour change, and ongoing support. Nobody should be left alone with a strong drug and a printout.
The phrase that lands hardest is the last one. Nobody should be left alone with a strong drug and a printout. It captures the specific failure mode that the GLP-1 revolution has created: a class of medications that genuinely work, that doctors are prescribing at scale, but that are being used in contexts where the monitoring, the nutritional guidance, the psychological support, and the metabolic assessment required to make them work safely and sustainably are absent. MetaGO was built to be what the drug alone is not.
Varun Sheth — the CEO Building the Healthcare Infrastructure
Varun Sheth, Co-Founder and CEO of both MetaGO and Ketto, brings the specific operational experience of building a platform used by millions of Indian families navigating healthcare challenges. Named in Forbes Under 30 and among India's Best 40 Under 40 Entrepreneurs, he is the operational lead who translates the founding vision into the systems, partnerships, and care delivery infrastructure that the platform requires.
His articulation of the MetaGO vision connects the company's launch to a larger structural shift in Indian healthcare: the country has made significant progress in expanding access to healthcare, and the next opportunity lies in making long-term metabolic care more continuous and connected. MetaGO is built around that idea — doctor-led from day one, delivered to the doorstep, designed around the member's life. The ambition is to make the standard of care previously available only to a privileged few accessible to every Indian who needs it.
The democratisation framing is specific and important. The integrated metabolic health management model that MetaGO is offering — comprehensive diagnostics, specialist-designed treatment plans, appropriate medications, continuous coaching — has, until now, been accessible primarily to people who could afford private endocrinology, private nutrition counselling, private fitness coaching, and private monitoring services simultaneously. Most Indians managing diabetes, obesity, or related metabolic conditions are doing so with fragmented care: a GP visit here, a lab test there, a medication prescribed without the monitoring to know if it is working safely.
MetaGO's model is an attempt to make the integrated version of that care available at a price and a format that makes it genuinely accessible.
The Mumbai Police Camp — Community Outreach as Proof of Principle
Before the formal launch, MetaGO conducted a free metabolic health camp for the Mumbai Police — offering blood tests and on-the-spot physician consultations to officers who wanted to understand their own metabolic health status.
The choice of the Mumbai Police as the initial community outreach target is deliberate and revealing. Police officers work irregular hours, experience high chronic stress, have limited access to structured healthcare during shifts, and face elevated rates of lifestyle-related metabolic conditions that are well-documented in occupational health research. They are also a professional group that is unlikely to self-navigate the specialist healthcare system — and likely to respond to a structured, authoritative, physician-led assessment model that is brought to them rather than requiring them to seek it.
The camp is both community service and proof of principle: evidence that the MetaGO model works in a real-world deployment, that the 35-biomarker assessment can be conducted efficiently at scale, and that the physician consultations on the back of that assessment generate the kind of immediate clinical value that participants will remember and recommend.
The company plans to expand similar initiatives to additional professional groups in the coming months.
The Market MetaGO Is Entering
India has more than 100 million people with Type 2 diabetes — the largest diabetic population in the world. The obesity epidemic that underpins much of that diabetic burden is accelerating: the India Obesity Report 2023 found that nearly 40 per cent of urban Indian adults are either overweight or obese. GLP-1 medications are generating extraordinary commercial demand globally, with Indian pharmaceutical companies producing and marketing several GLP-1 options at price points significantly lower than their US or European equivalents.
The platform that provides the clinical infrastructure to make GLP-1 therapy safe, effective, and sustainable — the assessment, the monitoring, the coaching, the ongoing physician supervision — is a market that does not yet have a dominant provider in India. MetaGO is positioning itself for exactly that space.
The founders' 14 years of observing metabolic disease from the downstream end of the healthcare system — at the point of crisis, when families are raising money for surgery — gives them a specific and unusual perspective on where the intervention should have happened and what it should have looked like. MetaGO is the platform they wished had existed for the thousands of families they watched navigate healthcare emergencies that earlier intervention might have prevented.
It is a healthcare company born from the specific and personal observation of healthcare's failure. The founders believe that makes it more likely to succeed at what healthcare is supposed to do — keep people well, not just treat them when they are sick.
